Overcoming therapy resistance in EGFR-mutant lung cancer

被引：0
|
作者：
Antonio Passaro
Pasi A. Jänne
Tony Mok
Solange Peters
机构：
[1] IRCCS,Division of Thoracic Oncology, European Institute of Oncology
[2] Dana-Farber Cancer Institute and Harvard Medical School,Lowe Center for Thoracic Oncology
[3] Chinese University of Hong Kong,State Key Laboratory in Translational Oncology, Department of Clinical Oncology
[4] Centre Hospitalier Universitaire Vaudois (CHUV),Department of Oncology
来源：
Nature Cancer | 2021年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating mutations. Despite prolonged disease control and high tumor response rates, all patients eventually progress on EGFR TKI treatment. Here, we review the mechanisms of acquired EGFR TKI resistance, the methods for monitoring its appearance, as well as current and future efforts to define treatment strategies to overcome resistance.
引用
收藏
页码：377 / 391
页数：14
相关论文
共 50 条
  • [1] Overcoming therapy resistance in EGFR-mutant lung cancer
    Passaro, Antonio
    Janne, Pasi A.
    Mok, Tony
    Peters, Solange
    [J]. NATURE CANCER, 2021, 2 (04) : 377 - 391
  • [2] Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy
    Kim, Jihye
    Vasu, Vihas T.
    Mishra, Rangnath
    Singleton, Katherine R.
    Yoo, Minjae
    Leach, Sonia M.
    Farias-Hesson, Eveline
    Mason, Robert J.
    Kang, Jaewoo
    Ramamoorthy, Preveen
    Kern, Jeffrey A.
    Heasley, Lynn E.
    Finigan, James H.
    Tan, Aik Choon
    [J]. BIOINFORMATICS, 2014, 30 (17) : 2393 - 2398
  • [3] Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
    Nakagawa, Takayuki
    Takeuchi, Shinji
    Yamada, Tadaaki
    Nanjo, Shigeki
    Ishikawa, Daisuke
    Sano, Takako
    Kita, Kenji
    Nakamura, Takahiro
    Matsumoto, Kunio
    Suda, Kenichi
    Mitsudomi, Tetsuya
    Sekido, Yoshitaka
    Uenaka, Toshimitsu
    Yano, Seiji
    [J]. MOLECULAR CANCER THERAPEUTICS, 2012, 11 (10) : 2149 - 2157
  • [4] Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma
    Kaira, Kyoichi
    Imai, Hisao
    Kagamu, Hiroshi
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 1177 - 1182
  • [5] Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
    Lee, Jiyun
    Piotrowska, Zofia
    Soo, Ross
    Cho, Byoung Chul
    Lim, Sun Min
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [6] Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer
    Piotrowska, Zofia
    Sequist, Lecia V.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) : 419 - 421
  • [7] Enhancing apoptosis to improve the therapy of EGFR-mutant lung cancer
    Tanaka, Kosuke
    Han, Song
    Ganesan, Yogesh T.
    Hsieh, James J.
    Cheng, Emily H.
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [8] Afatinib—new therapy option for EGFR-mutant lung cancer
    Helena A. Yu
    William Pao
    [J]. Nature Reviews Clinical Oncology, 2013, 10 : 551 - 552
  • [9] Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas
    Pirazzoli, Valentina
    Takezawa, Ken
    de Stanchina, Elisa
    Pao, William
    Politi, Katerina
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [10] Improving Therapy for EGFR-Mutant Lung Cancers
    Piotrowska, Zofia
    [J]. ONCOLOGIST, 2017, 22 : S4 - S4
12345